## **Scott H Kollins**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/884111/publications.pdf

Version: 2024-02-01

202 papers 10,138 citations

53 h-index 92 g-index

212 all docs 212 docs citations

times ranked

212

8092 citing authors

#	Article	IF	CITATIONS
1	Parenting Stress, Child Weight-Related Behaviors, and Child Weight Status. Childhood Obesity, 2022, 18, 150-159.	1.5	3
2	Regularity and Timing of Sleep Patterns and Behavioral Health Among Adolescents. Journal of Developmental and Behavioral Pediatrics, 2022, 43, 188-196.	1.1	2
3	Impact of daily caffeine intake and timing on electroencephalogram-measured sleep in adolescents. Journal of Clinical Sleep Medicine, 2022, 18, 877-884.	2.6	13
4	Editorial: <i>The gathering storm </i> : a US perspective on the scientific response to the COVIDâ€19 child and adolescent mental health crisis. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2022, 63, 129-131.	5.2	3
5	Shuffle the Decks: Children Are Sensitive to Incidental Nonrandom Structure in a Sequential-Choice Task. Psychological Science, 2022, , 095679762110420.	3.3	O
6	Sleep onset, duration, or regularity: which matters most for child adiposity outcomes?. International Journal of Obesity, 2022, 46, 1502-1509.	3.4	6
7	0499 Sleep and Neurocognition in Adolescents with ADHD: A Polysomnographic Study. Sleep, 2022, 45, A221-A221.	1.1	0
8	Eveningness Diurnal Preference: Putting the "Sluggish―in Sluggish Cognitive Tempo. Journal of Attention Disorders, 2021, 25, 2060-2067.	2.6	10
9	Sluggish Cognitive Tempo in Adults Referred for an ADHD Evaluation: A Psychometric Analysis of Selfand Collateral Report. Journal of Attention Disorders, 2021, 25, 322-331.	2.6	12
10	Attention-deficit/hyperactivity disorder and the explore/exploit trade-off. Neuropsychopharmacology, 2021, 46, 614-621.	5.4	15
11	It Is Time to REACT: Opportunities for Digital Mental Health Apps to Reduce Mental Health Disparities in Racially and Ethnically Minoritized Groups. JMIR Mental Health, 2021, 8, e25456.	3.3	58
12	Editorial: Is child mental health research structurally racist?. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 111-113.	5.2	5
13	A scalable computational approach to assessing response to name in toddlers with autism. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1120-1131.	5.2	19
14	Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD. Npj Digital Medicine, 2021, 4, 58.	10.9	28
15	Pharmacotherapy for Preschool Children with Attention Deficit Hyperactivity Disorder (ADHD): Current Status and Future Directions. CNS Drugs, 2021, 35, 403-424.	5.9	12
16	Computational Methods to Measure Patterns of Gaze in Toddlers With Autism Spectrum Disorder. JAMA Pediatrics, 2021, 175, 827-836.	6.2	44
17	DNA Methylation in Babies Born to Nonsmoking Mothers Exposed to Secondhand Smoke during Pregnancy: An Epigenome-Wide Association Study. Environmental Health Perspectives, 2021, 129, 57010.	6.0	15
18	600 Differential Impact of Overnight Delta Power Dynamics on Neurocognition among Adolescents with ADHD versus Healthy Controls. Sleep, 2021, 44, A236-A236.	1.1	0

#	Article	IF	CITATIONS
19	Smoke-Free Home Rules and Association with Child Secondhand Smoke Exposure among Mother–Child Dyad Relationships. International Journal of Environmental Research and Public Health, 2021, 18, 5256.	2.6	2
20	Reactions to reduced nicotine content cigarettes in a sample of young adult, low-frequency smokers. Psychopharmacology, 2021, 238, 2429-2438.	3.1	2
21	Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 342-349.	1.3	3
22	The role of machine learning in clinical research: transforming the future of evidence generation. Trials, 2021, 22, 537.	1.6	82
23	Refraining from use diminishes cannabis-associated epigenetic changes in human sperm. Environmental Epigenetics, 2021, 7, dvab009.	1.8	41
24	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 2021, 128, 789-818.	6.1	483
25	A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 597-609.	1.3	21
26	Associations between maternal obesity, gestational cytokine levels and child obesity in the <scp>NEST</scp> cohort. Pediatric Obesity, 2021, 16, e12763.	2.8	15
27	Identifying the Best Questions for Rapid Screening of Secondhand Smoke Exposure Among Children. Nicotine and Tobacco Research, 2021, 23, 1217-1223.	2.6	4
28	Large-scale genetic investigation reveals genetic liability to multiple complex traits influencing a higher risk of ADHD. Scientific Reports, 2021, 11, 22628.	3.3	8
29	Effect of Prenatal Smoke Exposure on Birth Weight: The Moderating Role of Maternal Depressive Symptoms. Nicotine and Tobacco Research, 2020, 22, 40-47.	2.6	6
30	Cannabis use is associated with potentially heritable widespread changes in autism candidate gene <i>DLGAP2</i> DNA methylation in sperm. Epigenetics, 2020, 15, 161-173.	2.7	61
31	Increased subjective and reinforcing effects of initial nicotine exposure in young adults with attention deficit hyperactivity disorder (ADHD) compared to matched peers: results from an experimental model of first-time tobacco use. Neuropsychopharmacology, 2020, 45, 851-856.	5.4	7
32	5.27 STARS-ADJUNCT: AKL-T01, A HOME-BASED DIGITAL INTERVENTION AS AN ADJUNCT TO STIMULANT MEDICATION FOR PEDIATRIC ADHD: ACADEMIC PERFORMANCE AND RELATION TO OBJECTIVE MEASURES OF ATTENTION. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S157-S158.	0.5	0
33	5.10 EFFICACY AND SAFETY OF AN EXTENDED-RELEASE, ORALLY DISINTEGRATING METHYLPHENIDATE TABLET IN CHILDREN 6-12 YEARS OF AGE BASED ON ADHD RATING SCALE-IV SCORE AT BASELINE. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S152.	0.5	O
34	5.13 EXPLORING ENGAGEMENT AS A FACTOR FOR EFFICACY WITH AKL-T01, A HOME-BASED DIGITAL THERAPEUTIC. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S153.	0.5	0
35	5.25 STARS-ADJUNCT: A HOME-BASED, DIGITAL TREATMENT FOR PEDIATRIC ADHD AS ADJUNCT TO STIMULANT MEDICATION: INSIGHTS ON REPEAT ADMINISTRATION AND THE STABILITY OF EFFECTS. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S157.	0.5	O
36	5.26 STARS-ADJUNCT: AKL-T01, A DIGITAL TREATMENT FOR PEDIATRIC ADHD AS AN ADJUNCT TO STIMULANT MEDICATION: RESPONSE RATES WITH REPEAT ADMINISTRATION. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S157.	0.5	0

#	Article	IF	CITATIONS
37	Sluggish cognitive tempo (SCT) in an adult outpatient sample seeking an attention-deficit/hyperactivity disorder assessment: Age of onset and assessment method impact on SCT rates. Journal of Psychiatric Research, 2020, 131, 203-208.	3.1	4
38	Health system utilization before age 1 among children later diagnosed with autism or ADHD. Scientific Reports, 2020, 10, 17677.	3.3	9
39	A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. Paediatric Drugs, 2020, 22, 561-570.	3.1	4
40	Associations between attention deficit hyperactivity disorder symptoms and eating behaviors in early childhood. Pediatric Obesity, 2020, 15, e12631.	2.8	14
41	Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2020, 30. 58-68.	1.3	13
42	A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. The Lancet Digital Health, 2020, 2, e168-e178.	12.3	186
43	Sleep/Wake Regularity Associated with Default Mode Network Structure among Healthy Adolescents and Young Adults. Scientific Reports, 2020, 10, 509.	3.3	34
44	Editorial: From risk prediction to action: leveraging electronic health records to improve pediatric population mental health. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2020, 61, 113-115.	5.2	2
45	Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 128-136.	1.3	8
46	Feasibility and Acceptability of Wearable Sleep Electroencephalogram Device Use in Adolescents: Observational Study. JMIR MHealth and UHealth, 2020, 8, e20590.	3.7	9
47	The Many Channels of Screen Media Technology in ADHD: a Paradigm for Quantifying Distinct Risks and Potential Benefits. Current Psychiatry Reports, 2019, 21, 90.	4.5	8
48	Snacking frequency and dietary intake in toddlers and preschool children. Appetite, 2019, 142, 104369.	3.7	16
49	37.4 COMPUTER-BASED AND PARENT-REPORTED ASSESSMENT OF EXECUTIVE FUNCTIONING: METHOD VARIANCE AND IMPLICATIONS FOR INTERPRETING FINDINGS FROM ADHD EFFICACY TRIALS. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, S356.	0.5	0
50	Duration of Effect of a Novel, Home-Based, Digital Treatment for Pediatric ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, S296.	0.5	0
51	A Generic Algorithm for Sleep-Wake Cycle Detection using Unlabeled Actigraphy Data. , 2019, , .		4
52	Smoking abstinence effects on emotion dysregulation in adult cigarette smokers with and without attention-deficit/hyperactivity disorder. Drug and Alcohol Dependence, 2019, 205, 107594.	3.2	6
53	Adaptations to Behavioral Parent Training for Children with ADHD: Promoting Access, Engagement, and Treatment Effectiveness. The ADHD Report, 2019, 27, 1-6,10,11,12.	0.6	3
54	Methylphenidate increases willingness to perform effort in adults with ADHD. Pharmacology Biochemistry and Behavior, 2019, 183, 14-21.	2.9	13

#	Article	IF	Citations
55	Driving the Point Home: Novel Approaches to Mitigate Crash Risk for Patients With ADHD. Pediatrics, 2019, 143, e20190820.	2.1	o
56	Pre-Pregnancy Weight and Symptoms of Attention Deficit Hyperactivity Disorder and Executive Functioning Behaviors in Preschool Children. International Journal of Environmental Research and Public Health, 2019, 16, 667.	2.6	20
57	Eveningness diurnal preference associated with poorer socioemotional cognition and social functioning among healthy adolescents and young adults. Chronobiology International, 2019, 36, 439-444.	2.0	5
58	Cigarette Smoking Progression Among Young Adults Diagnosed With ADHD in Childhood: A 16-year Longitudinal Study of Children With and Without ADHD. Nicotine and Tobacco Research, 2019, 21, 638-647.	2.6	21
59	An Automated Text-Messaging Platform for Enhanced Retention and Data Collection in a Longitudinal Birth Cohort: Cohort Management Platform Analysis. JMIR Public Health and Surveillance, 2019, 5, e11666.	2.6	2
60	Associations between maternal cytokine levels during gestation and measures of child cognitive abilities and executive functioning. Brain, Behavior, and Immunity, 2018, 70, 390-397.	4.1	30
61	Reliability and Validity of the Daily Parent Rating of Evening and Morning Behavior Scale, Revised. Journal of Attention Disorders, 2018, 22, 1066-1073.	2.6	10
62	How Substance Users With ADHD Perceive the Relationship Between Substance Use and Emotional Functioning. Journal of Attention Disorders, 2018, 22, 49S-60S.	2.6	19
63	Childhood ADHD Symptoms and Future Illicit Drug Use: The Role of Adolescent Cigarette Use. Journal of Pediatric Psychology, 2018, 43, 162-171.	2.1	5
64	ADHD, Smoking Withdrawal, and Inhibitory Control: Results of a Neuroimaging Study with Methylphenidate Challenge. Neuropsychopharmacology, 2018, 43, 851-858.	5.4	12
65	4.15 The Efficacy and Safety of Methylphenidate Hydrochloride (HCL) Extended-Release in Preschool Aged Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, S209.	0.5	2
66	2.40 A Multicenter, Randomized, Active-Control Registration Trial of Software Treatment for Actively Reducing Severity of ADHD (Stars-Adhd) to Assess the Efficacy and Safety of a Novel, Home-Based, Digital Treatment for Pediatric ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, S172.	0.5	3
67	Cannabinoid exposure and altered DNA methylation in rat and human sperm. Epigenetics, 2018, 13, 1208-1221.	2.7	160
68	Validation of the Sleep Regularity Index in Older Adults and Associations with Cardiometabolic Risk. Scientific Reports, 2018, 8, 14158.	3.3	120
69	2.22 Lisdexamfetamine Dimesylate for Preschool Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, S165-S166.	0.5	0
70	Editorial Perspective: Delayed circadian rhythm phase: a cause of lateâ€onset attentionâ€deficit/hyperactivity disorder among adolescents?. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2018, 59, 1248-1251.	5.2	15
71	Impact of Smoking Ban on Passive Smoke Exposure in Pregnant Non-Smokers in the Southeastern United States. International Journal of Environmental Research and Public Health, 2018, 15, 83.	2.6	15
72	Self-reported prenatal tobacco smoke exposure, AXL gene-body methylation, and childhood asthma phenotypes. Clinical Epigenetics, 2018, 10, 98.	4.1	15

#	Article	IF	Citations
73	Moving Beyond Symptom Remission to Optimize Long-term Treatment of Attention-Deficit/Hyperactivity Disorder. JAMA Pediatrics, 2018, 172, 901.	6.2	15
74	Proof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD. PLoS ONE, 2018, 13, e0189749.	2.5	69
75	Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 66-74.	1.3	36
76	Prenatal Smoke Exposure and ADHD: Advancing the Field. Pediatrics, 2017, 139, .	2.1	7
77	21.2 Substance Use Among Children With and Without Attention-Deficit/Hyperactivity Disorder Followed Prospectively Into Early Adulthood in the MTA. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, S334-S335.	0.5	0
78	Maternal inflammatory diet and adverse pregnancy outcomes: Circulating cytokines and genomic imprinting as potential regulators?. Epigenetics, 2017, 12, 688-697.	2.7	68
79	A Pilot Trial of Mindfulness Meditation Training for ADHD in Adulthood: Impact on Core Symptoms, Executive Functioning, and Emotion Dysregulation. Journal of Attention Disorders, 2017, 21, 1105-1120.	2.6	133
80	6.41 A SIX-MONTH OPEN-LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF PRC-063 IN ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S217.	0.5	2
81	6.42 A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY MEASURING THE EFFICACY AND SAFETY OF A NOVEL, EXTENDED-RELEASE FORMULATION OF METHYLPHENIDATE (PRC-063) IN ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S217-S218.	0.5	3
82	Sleep disturbances in adolescents with ADHD: A systematic review and framework for future research. Clinical Psychology Review, 2016, 50, 159-174.	11.4	83
83	Topical Review: ADHD and Health-Risk Behaviors: Toward Prevention and Health Promotion. Journal of Pediatric Psychology, 2016, 41, 735-740.	2.1	44
84	"l Use Weed for My ADHD― A Qualitative Analysis of Online Forum Discussions on Cannabis Use and ADHD. PLoS ONE, 2016, 11, e0156614.	2.5	84
85	Pharmacotherapy of the Preschool ADHD Treatment StudyÂ(PATS) Children Growing Up. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 550-556.	0.5	30
86	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology, 2015, 40, 2745-2752.	5.4	47
87	Mindfulness Meditation Training for Attention-Deficit/Hyperactivity Disorder in Adulthood: Current Empirical Support, Treatment Overview, and Future Directions. Cognitive and Behavioral Practice, 2015, 22, 172-191.	1.5	79
88	Attention Deficit Hyperactivity Disorder symptoms and smoking trajectories: Race and gender differences. Drug and Alcohol Dependence, 2015, 148, 180-187.	3.2	8
89	The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 402-414.	1.3	21
90	An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. Journal of Substance Abuse Treatment, 2015, 48, 96-103.	2.8	28

#	Article	IF	CITATIONS
91	Angiogenic, neurotrophic, and inflammatory system SNPs moderate the association between birth weight and ADHD symptom severity. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 691-704.	1.7	29
92	Combined Ecological Momentary Assessment and Global Positioning System Tracking to Assess Smoking Behavior: A Proof of Concept Study. Journal of Dual Diagnosis, 2014, 10, 19-29.	1.2	34
93	A Randomized Placebo-Controlled Double-Blind Study Evaluating the Time Course of Response to Methylphenidate Hydrochloride Extended-Release Capsules in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 562-569.	1.3	34
94	Smoking Motivation in Adults With Attention-Deficit/Hyperactivity Disorder Using the Wisconsin Inventory of Smoking Dependence Motives. Nicotine and Tobacco Research, 2014, 16, 120-125.	2.6	9
95	Ecological Momentary Assessment of Antecedents and Consequences of Smoking in Adults with Attention-Deficit/Hyperactivity Disorder. Substance Use and Misuse, 2014, 49, 1446-1456.	1.4	17
96	Steady-State Bioavailability of Extended-Release Methylphenidate (MPH-MLR) Capsule vs. Immediate-Release Methylphenidate Tablets in Healthy Adult Volunteers. Clinical Drug Investigation, 2014, 34, 795-805.	2.2	16
97	A Pilot Study of Lis-Dexamfetamine Dimesylate (LDX/SPD489) to Facilitate Smoking Cessation in Nicotine-Dependent Adults With ADHD. Journal of Attention Disorders, 2014, 18, 158-168.	2.6	21
98	ADHD, altered dopamine neurotransmission, and disrupted reinforcement processes: Implications for smoking and nicotine dependence. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 52, 70-78.	4.8	51
99	Stimulant Treatment of ADHD and Cigarette Smoking: A Meta-Analysis. Pediatrics, 2014, 133, 1070-1080.	2.1	46
100	Prevention of Health Risk Behaviors in ADHD Youth: Is ADHD Treatment Enough?. The ADHD Report, 2014, 22, 1-8.	0.6	4
101	Effects of smoking abstinence on smoking-reinforced responding, withdrawal, and cognition in adults with and without attention deficit hyperactivity disorder. Psychopharmacology, 2013, 227, 19-30.	3.1	31
102	Nicotinic receptor gene variants interact with attention deficient hyperactive disorder symptoms to predict smoking trajectories from early adolescence to adulthood. Addictive Behaviors, 2013, 38, 2683-2689.	3.0	19
103	The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-Year Follow-Up. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 264-278.e2.	0.5	162
104	Individual- and community-level correlates of cigarette-smoking trajectories from age 13 to 32 in a U.S. population-based sample. Drug and Alcohol Dependence, 2013, 132, 301-308.	3.2	48
105	Childhood Economic Strains in Predicting Substance Use in Emerging Adulthood: Mediation Effects of Youth Self-Control and Parenting Practices. Journal of Pediatric Psychology, 2013, 38, 1130-1143.	2.1	20
106	Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD) Experimental and Clinical Psychopharmacology, 2013, 21, 375-384.	1.8	5
107	Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate. Neuropsychiatric Disease and Treatment, 2013, 10, 1.	2.2	8
108	Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder. PLoS ONE, 2013, 8, e63023.	2.5	99

#	Article	IF	CITATIONS
109	Attention-Deficit/Hyperactivity Disorder in Adolescence. , 2013, , 423-445.		О
110	An examination of differences in variables maintaining smoking behavior in adult smokers with and without attention-deficit/hyperactivity disorder. Addiction Research and Theory, 2012, 20, 72-81.	1.9	12
111	Methylphenidate-Elicited Dopamine Increases in Ventral Striatum Are Associated with Long-Term Symptom Improvement in Adults with Attention Deficit Hyperactivity Disorder. Journal of Neuroscience, 2012, 32, 841-849.	3.6	181
112	Assessing the Role of Attention-Deficit/Hyperactivity Disorder Symptoms in Smokers With and Without Posttraumatic Stress Disorder. Nicotine and Tobacco Research, 2012, 14, 986-992.	2.6	8
113	Dose Response Effects of Lisdexamfetamine Dimesylate Treatment in Adults With ADHD. Journal of Attention Disorders, 2012, 16, 118-127.	2.6	8
114	A Preliminary Analysis of Interactions Between Genotype, Retrospective ADHD Symptoms, and Initial Reactions to Smoking in a Sample of Young Adults. Nicotine and Tobacco Research, 2012, 14, 229-233.	2.6	19
115	Efficacy of Guanfacine Extended Release in the Treatment of Combined and Inattentive Only Subtypes of Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 206-214.	1.3	27
116	Understanding the Phenotypic Structure of Adult Retrospective ADHD Symptoms During Childhood in the United States. Journal of Clinical Child and Adolescent Psychology, 2012, 41, 261-274.	3.4	18
117	Emotion Dysregulation and Emotional Impulsivity among Adults with Attention-Deficit/Hyperactivity Disorder: Results of a Preliminary Study. Journal of Psychopathology and Behavioral Assessment, 2012, 34, 510-519.	1.2	38
118	Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder. Neurotherapeutics, 2012, 9, 518-530.	4.4	114
119	Sex, ADHD symptoms, and smoking outcomes: An integrative model. Medical Hypotheses, 2012, 78, 585-593.	1.5	23
120	Psychomotor Functioning and Alertness with Guanfacine Extended Release in Subjects with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 111-120.	1.3	46
121	Clonidine Extended-Release Tablets for Pediatric Patients With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 171-179.	0.5	112
122	Cognitive enhancers for the treatment of ADHD. Pharmacology Biochemistry and Behavior, 2011, 99, 262-274.	2.9	86
123	The <i>ATXN1</i> and <i>TRIM31</i> genes are related to intelligence in an ADHD background: Evidence from a large collaborative study totaling 4,963 Subjects. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 145-157.	1.7	21
124	A Double-Blind, Placebo-Controlled Study of Atomoxetine in Young Children With ADHD. Pediatrics, 2011, 127, e862-e868.	2.1	58
125	Self-Regulation of Emotion, Functional Impairment, and Comorbidity Among ChildrenWith AD/HD. Journal of Attention Disorders, 2011, 15, 583-592.	2.6	211
126	Smoking Withdrawal Symptoms Are More Severe Among Smokers With ADHD and Independent of ADHD Symptom Change: Results From a 12-Day Contingency-Managed Abstinence Trial. Nicotine and Tobacco Research, 2011, 13, 784-792.	2.6	43

#	Article	IF	Citations
127	Clonidine Extended-Release Tablets as Add-on Therapy to Psychostimulants in Children and Adolescents With ADHD. Pediatrics, 2011, 127, e1406-e1413.	2.1	113
128	Reliability and Validity of Self- and Other-Ratings of Symptoms of ADHD in Adults. Journal of Attention Disorders, 2011, 15, 224-234.	2.6	45
129	Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. Innovations in Clinical Neuroscience, 2011, 8, 28-32.	0.1	11
130	Genetic variants in SLC9A9 are associated with measures of Attention-deficit/hyperactivity disorder symptoms in families. Psychiatric Genetics, 2010, 20, 73-81.	1.1	44
131	Monetary incentives promote smoking abstinence in adults with attention deficit hyperactivity disorder (ADHD) Experimental and Clinical Psychopharmacology, 2010, 18, 221-228.	1.8	21
132	Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 24-32.	0.5	20
133	Implications of Extending the ADHD Age-of-Onset Criterion to Age 12. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 210-216.	0.5	8
134	Alpha-2 Adrenergic Receptors and Attention-Deficit/Hyperactivity Disorder. Current Psychiatry Reports, 2010, 12, 366-373.	4.5	41
135	Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. Child and Adolescent Psychiatry and Mental Health, 2010, 4, 32.	2.5	20
136	Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opinion on Pharmacotherapy, 2010, 11, 2907-2913.	1.8	13
137	Guide to Assessment Scales in Attention-deficit/Hyperactivity Disorder. , 2010, , .		6
138	Smoking Withdrawal Modulates Right Inferior Frontal Cortex but not Presupplementary Motor Area Activation During Inhibitory Control. Neuropsychopharmacology, 2010, 35, 2600-2606.	5.4	43
139	Implications of Extending the ADHD Age-of-Onset Criterion to Age 12: Results from a Prospectively Studied Birth Cohort. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 210-216.	0.5	71
140	Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 24-32.	0.5	27
141	Implications of extending the ADHD age-of-onset criterion to age 12: results from a prospectively studied birth cohort. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 210-6.	0.5	61
142	Association between smoking and retrospectively reported attention-deficit/hyperactivity disorder symptoms in a large sample of new mothers. Nicotine and Tobacco Research, 2009, 11, 313-322.	2.6	9
143	Evaluating Dopamine Reward Pathway in ADHD. JAMA - Journal of the American Medical Association, 2009, 302, 1084.	7.4	518
144	Interactions Between Genotype and Depressive Symptoms on Obesity. Behavior Genetics, 2009, 39, 296-305.	2.1	15

#	Article	IF	Citations
145	Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology, 2009, 204, 73-83.	3.1	41
146	A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatry and Mental Health, 2009, 3, 17.	2.5	100
147	Effects of smoking abstinence on reaction time variability in smokers with and without ADHD: An ex-Gaussian analysis. Drug and Alcohol Dependence, 2009, 100, 169-172.	3.2	21
148	Effects of Postnatal Parental Smoking on Parent and Teacher Ratings of ADHD and Oppositional Symptoms. Journal of Nervous and Mental Disease, 2009, 197, 442-449.	1.0	19
149	Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. Psychopharmacology, 2008, 197, 95-105.	3.1	83
150	Psychosocial treatments for preschoolâ€aged children with Attentionâ€Deficit Hyperactivity Disorder. Developmental Disabilities Research Reviews, 2008, 14, 300-310.	2.9	22
151	Genes Implicated in Serotonergic and Dopaminergic Functioning Predict BMI Categories. Obesity, 2008, 16, 348-355.	3.0	78
152	Methylphenidate and Amphetamine Do Not Induce Cytogenetic Damage in Lymphocytes of Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 1375-1383.	0.5	28
153	ADHD, Substance Use Disorders, and Psychostimulant Treatment. Journal of Attention Disorders, 2008, 12, 115-125.	2.6	124
154	Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sample of young adults. Nicotine and Tobacco Research, 2008, 10, 117-127.	2.6	43
155	A qualitative review of issues arising in the use of psychoÂstimulant medications in patients with ADHD and co‑morbid substance use disorders. Current Medical Research and Opinion, 2008, 24, 1345-1357.	1.9	89
156	Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 2008, 69, 1364-1373.	2.2	191
157	A Pilot Study of Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 175-186.	1.3	42
158	Methylphenidate Effects on Functional Outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 581-592.	1.3	67
159	Effects of Source of DNA on Genotyping Success Rates and Allele Percentages in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 635-645.	1.3	8
160	Comorbidity Moderates Response to Methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 563-579.	1.3	67
161	Clinical Presentation of Attention-Deficit/Hyperactivity Disorder in Preschool Children: The Preschoolers with Attention-Deficit/Hyperactivity Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 547-562.	1.3	124
162	Parent versus Teacher Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 605-619.	1.3	85

#	Article	IF	CITATIONS
163	Effectiveness of Methylphenidate in the 10-Month Continuation Phase of the Preschoolers with ADHD Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 593-603.	1.3	55
164	Attention Deficit Hyperactivity Disorder Symptoms Predict Nicotine Dependence and Progression to Regular Smoking from Adolescence to Young Adulthood. Journal of Pediatric Psychology, 2007, 32, 1203-1213.	2.1	105
165	Increases in impulsivity following smoking abstinence are related to baseline nicotine intake and boredom susceptibility. Addictive Behaviors, 2007, 32, 2351-2357.	3.0	27
166	Factor Structure of Parent- and Teacher-Rated Attention-Deficit/Hyperactivity Disorder Symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 621-633.	1.3	49
167	Advances in the Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2007, 62, 951-953.	1.3	15
168	ADHD and Sustance Abuse Update. American Journal on Addictions, 2007, 16, 1-4.	1.4	35
169	Abuse Liability of Medications Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD). American Journal on Addictions, 2007, 16, 35-44.	1.4	52
170	Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1284-1293.	0.5	409
171	Safety and Tolerability of Methylphenidate in Preschool Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1294-1303.	0.5	211
172	Pharmacogenetics of Methylphenidate Response in Preschoolers With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1314-1322.	0.5	116
173	Stimulant-Related Reductions of Growth Rates in the PATS. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1304-1313.	0.5	201
174	Rationale, Design, and Methods of the Preschool ADHD Treatment Study (PATS). Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1275-1283.	0.5	125
175	Evidence Base for the Use of Stimulant Medication in Preschool Children With ADHD. Infants and Young Children, 2006, 19, 132-141.	0.7	18
176	Psychometric Properties of an Adult ADHD Diagnostic Interview. Journal of Attention Disorders, 2006, 9, 504-514.	2.6	89
177	A Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR $\hat{A}^{\odot}$ ) and Atomoxetine (Strattera $\hat{A}^{\odot}$ ) in School-Aged Children With Attention Deficit/Hyperactivity Disorder. Journal of Attention Disorders, 2005, 9, 275-289.	2.6	126
178	A Pilot Study of Methylphenidate Preference Assessment in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 729-741.	1.3	18
179	Association Between Smoking and Attention-Deficit/Hyperactivity Disorder Symptoms in a Population-Based Sample of Young Adults. Archives of General Psychiatry, 2005, 62, 1142.	12.3	308
180	Comments on ‴Cytogenetic effects in children treated with methylphenidate' by El-Zein et al Cancer Letters, 2005, 230, 292-294.	7.2	23

#	Article	IF	CITATIONS
181	Methodological Issues in the Assessment of Medication Effects in Children Diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Journal of Behavioral Education, 2004, 13, 247-266.	1.3	3
182	Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology, 2004, 175, 391-8.	3.1	21
183	A Comparison of Once-Daily Extended-Release Methylphenidate Formulations in Children With Attention-Deficit/Hyperactivity Disorder in the Laboratory School (The Comacs Study). Pediatrics, 2004, 113, e206-e216.	2.1	206
184	Delay discounting is associated with substance use in college students. Addictive Behaviors, 2003, 28, 1167-1173.	3.0	224
185	Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Journal of Clinical Psychiatry, 2003, 64 Suppl 11, 14-8.	2.2	33
186	Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. Biological Psychiatry, 2002, 51, 143-150.	1.3	15
187	TEMPORAL DISCOUNTING: BASIC RESEARCH AND THE ANALYSIS OF SOCIALLY IMPORTANT BEHAVIOR. Journal of Applied Behavior Analysis, 2001, 34, 101-122.	2.7	334
188	Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacology Biochemistry and Behavior, 2001, 68, 611-627.	2.9	307
189	Use and Management of Medications for Children Diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Focus on Exceptional Children, 2001, 33, .	0.7	0
190	The good, the bad, and the aggregate. The Behavior Analyst, 2000, 23, 107-115.	2.5	8
191	EFFECTS OF METHYLPHENIDATE ON SENSITIVITY TO REINFORCEMENT IN CHILDREN DIAGNOSED WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER: AN APPLICATION OF THE MATCHING LAW. Journal of Applied Behavior Analysis, 2000, 33, 573-591.	2.7	58
192	Factors Affecting the Reliability of Clinical Judgments About the Function of Children's School-Refusal Behavior. Journal of Clinical Child and Adolescent Psychology, 1999, 28, 396-406.	2.1	16
193	Behavioural assessment of children and adolescents. Indian Journal of Pediatrics, 1999, 66, 389-399.	0.8	2
194	Effects of Training Dose on the Relationship Between Discriminative-Stimulus and Self-Reported Drug Effects of d-Amphetamine in Humans. Pharmacology Biochemistry and Behavior, 1999, 64, 319-326.	2.9	21
195	Has behavior therapy drifted from its experimental roots? a survey of publication trends in mainstream behavioral journals. Journal of Behavior Therapy and Experimental Psychiatry, 1999, 30, 205-220.	1.2	3
196	Quantitative integration of single-subject studies: Methods and misinterpretations. The Behavior Analyst, 1999, 22, 149-157.	2.5	9
197	Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate Experimental and Clinical Psychopharmacology, 1998, 6, 367-374.	1.8	91
198	Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans Experimental and Clinical Psychopharmacology, 1998, 6, 32-44.	1.8	96

## SCOTT H KOLLINS

#	Article	IF	CITATIONS
199	Discriminative and participant-rated effects of methylphenidate in children diagnosed with attention deficit hyperactivity disorder (ADHD) Experimental and Clinical Psychopharmacology, 1998, 6, 375-389.	1.8	18
200	Experimental analysis of childhood psychopathology: A laboratory matching analysis of the behavior of children diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD). Psychological Record, 1997, 47, 25-44.	0.9	80
201	Human sensitivity to reinforcement in operant choice: How much do consequences matter?. Psychonomic Bulletin and Review, 1997, 4, 208-220.	2.8	71
202	Abuse potential of stimulant drugs used to treat ADHD., 0,, 230-239.		0